ABSTRACT
This study aimed to assess the antiviral susceptibility of influenza A(H5N8) viruses isolated in Russia in 2014-2018. Genetic analysis of 57 Russian isolates with full genome sequences did not find any markers of reduced susceptibility to baloxavir. Only one strain bore an amino acid substitution associated with adamantane resistance (M2-S31N). The neuraminidase of 1 strain had an NA-N293/294S (N8/N2 numbering) substitution associated with reduced inhibition by oseltamivir and normal inhibition by zanamivir, which was confirmed phenotypically. There were no other strains with reduced inhibition by oseltamivir and zanamivir in the phenotypic analysis. In order to estimate the worldwide prevalence of influenza A(H5N8) viruses bearing genetic markers of antiviral resistance, genome sequences deposited in the GISAID database were analyzed (database access: October 2020). The M2 protein of A(H5N8) viruses from the 2.3.4.4c clade had an M2-S31N substitution associated with reduced susceptibility to adamantanes. On the contrary, the majority (94%) of viruses from the 2.3.4.4b clade had the M2-S31 genotype. Fewer than 1% of analyzed viruses had amino acid substitutions associated with reduced susceptibility to baloxavir (PA-E199G, PA-E199E/G) or reduced or highly reduced inhibition by neuraminidase inhibitors (NA-R150/152K, NA-I221/222M, NA-I221/222I/M, NA-I221/222V, NA-I115/117V, NA-G145/147R, NA-R291/292R/K). An NA-N293/294S substitution was not present in sequences from the GISAID database. To the best of our knowledge, influenza A(H5N8) viruses with reduced inhibition by oseltamivir bearing an NA-N293/294S substitution have not been previously reported in epidemiological surveillance studies.
Subject(s)
Amino Acid Substitution/genetics , Antiviral Agents/pharmacology , Disease Outbreaks/veterinary , Influenza A Virus, H5N8 Subtype/drug effects , Influenza A Virus, H5N8 Subtype/genetics , Neuraminidase/genetics , Orthomyxoviridae Infections/veterinary , Oseltamivir/pharmacology , Poultry/virology , Animals , Drug Resistance, Viral/genetics , Farms/statistics & numerical data , Genetic Markers/genetics , Orthomyxoviridae Infections/epidemiology , Russia/epidemiology , Viral Proteins/geneticsABSTRACT
In late 2016, a highly pathogenic avian influenza (HPAI) virus subtype H5N8 clade 2.3.4.4 was reported in Egypt in migratory birds; subsequently, the virus spread to backyard and commercial poultry in several Egyptian governorates, causing severe economic losses to the poultry industry. Here, a recombinant subunit commercial H5 vaccine prepared from the clade 2.3.2 H5 segment on baculovirus was evaluated in Pekin ducks (Anasplatyrhynchos domesticus) and Muscovy ducks (Cairina moschata) in Biosafety Level 3 isolators by using two vaccination regimes: either a single dose on day 10 and a challenge on day 31 or a double dose on days 10 and 28 and a challenge on day 49. The protection parameters were evaluated after experimental infection with the Egyptian HPAI H5N8 isolate clade 2.3.4.4b (A/common-coot/Egypt/CA285/2016) based on mortality rate, clinical signs, gross lesions, seroconversion, virus shedding, and histopathologic changes. In the single-dose vaccination regime, the mortality rate in Muscovy and Pekin ducks was 10% and 0% vs. 40% and 0% in nonvaccinated challenged ducks, respectively. In the double-dose vaccination regime, the mortality rates in Muscovy and Pekin ducks were 0% and 0% vs. 60% and 40% in nonvaccinated challenged ducks, respectively. Muscovy ducks developed more severe clinical signs and gross lesions than Pekin ducks. In addition, tracheal viral shedding in challenged Muscovy ducks, in the single-dose vaccination regime, was 50%, 22%, and 0% at 3, 5, and 7 days postchallenge (DPC), respectively, and was 0% in all Pekin ducks vs. 100% in all challenged nonvaccinated Muscovy and Pekin ducks at 3, 5, and 7 DPC. The viral shedding in challenged Muscovy and Pekin ducks, in the double-dose vaccination regime, was 0% at 3, 5, and 7 DPC vs. 100% in nonvaccinated challenged Muscovy and Pekin ducks, respectively. The results of this study indicate that the H5 baculovirus-based vaccine can be used in ducks with better vaccination regime based on double-dose vaccination at 10 and 28 days of age. In addition, they highlight the need to evaluate the efficacy of currently used commercial vaccines against challenge with the newly emerged HPAI H5N8 clade 2.3.4.4 in the field in Egypt to ensure proper control strategy in ducks.
Eficacia de una vacuna desarrollada con un baculovirus recombinante subtipo H5 clado 2.3.2 en la protección de patos reales y Pekín contra la infección con virus de la influenza aviar de alta patogenicidad subtipo H5N8, clado 2.3.4.4. A finales del año 2016, se reportó en aves migratorias en Egipto la presencia del virus de la influenza aviar de alta patogenicidad subtipo H5N8, clado 2.3.4.4. Posteriormente, el virus se propagó en aves de traspatio y comerciales de varias provincias egipcias, causando graves pérdidas económicas a la industria avícola. En este trabajo, una vacuna subunitaria recombinante comercial con el subtipo H5 preparada a partir del segmento H5 del clado 2.3.2 expresado en baculovirus se evaluó en patos de Pekín y reales en unidades de aislamiento con nivel de bioseguridad 3 utilizando dos esquemas de vacunación: una dosis única en el día 10 y un desafío el día 31; o un esquema con doble dosis en los días 10 y 28 y con un desafío en el día 49. Los parámetros de protección se evaluaron después de la infección experimental con el aislamiento del virus de alta patogenicidad H5N8, clado 2.3.4.4b de Egipto (A/focha común/Egipto/ CA285/2016) con base en la tasa de mortalidad, signos clínicos, lesiones macroscópicas, seroconversión, eliminación del virus y cambios histopatológicos. Los resultados revelaron que la tasa de mortalidad en patos reales y Pekín, en un régimen de vacunación con dosis única fue de 10% y 0%, respectivamente en comparación con 40% y 0% en patos no vacunados y desafiados, respectivamente. En los patos reales y Pekín, con un esquema de vacunación con dosis doble, la tasa de mortalidad fue del 0% en comparación con 60% y 40% en los patos no vacunados y desafiados, respectivamente. Los patos reales desarrollaron signos clínicos y lesiones más severos en comparación con los patos Pekín. Además, la eliminación viral a partir de la tráquea en patos reales desafiados y con un esquema de vacunación de dosis única, fue del 50%, 22% y 0% a los 3, 5 y 7 días posteriores al desafío, respectivamente, y fue del 0% en todos los patos Pekín en comparación con el 100% en todos los patos reales y Pekín no vacunados y desafiados a los 3, 5 y 7 días después del desafío. La eliminación viral en los patos reales y Pekín desafiados, con un esquema de vacunación de dosis doble, fue de 0% a los tres, cinco y siete días después del desafío en comparación con el 100% en los patos reales y Pekín no vacunados y desafiados, respectivamente. Los resultados de este estudio indican que la vacuna basada en el baculovirus H5 se puede usar en patos con un mejor esquema de vacunación basado en la vacunación con dosis doble a los 10 y 28 días de edad. Además, se resalta la necesidad de evaluar la eficacia de las vacunas comerciales utilizadas actualmente contra el desafío con el nuevo virus de alta patogenicidad H5N8 clado 2.3.4.4 en el campo en Egipto para garantizar una estrategia de control adecuada en patos.
Subject(s)
Ducks , Influenza A Virus, H5N8 Subtype/drug effects , Influenza in Birds/prevention & control , Poultry Diseases/prevention & control , Viral Vaccines/pharmacology , Animals , Baculoviridae , Vaccines, Synthetic/pharmacologyABSTRACT
The most recent pandemic clade of highly pathogenic avian influenza (HPAI) H5, clade 2.3.4.4, spread widely, with the involvement of wild birds, most importantly wild waterfowl, carrying the virus (even asymptomatically) from Asia to North America, Europe, and Africa. Domestic waterfowl being in regular contact with wild birds played a significant role in the H5Nx epizootics. Therefore, protection of domestic waterfowl from H5Nx avian influenza infection would likely cut the transmission chain of these viruses and greatly enhance efforts to control and prevent disease outbreak in other poultry and animal species, as well as infection of humans. The expectation for such a vaccine is not only to provide clinical protection, but also to control challenge virus transmission efficiently and ensure that the ability to differentiate infected from vaccinated animals is retained. A water-in-oil emulsion virus-like particle vaccine, containing homologous hemagglutinin antigen to the current European H5N8 field strains, has been developed to meet these requirements. The vaccine was tested in commercial Pekin and mule ducks by vaccinating them either once, at 3 wk of age, or twice (at 1 day and at 3 wk of age). Challenge was performed at 6 wk of age with a Hungarian HPAIV H5N8 isolate (2.3.4.4 Group B). Efficacy of vaccination was evaluated on the basis of clinical signs, amount of virus shedding, and transmission. Vaccination resulted in complete clinical protection and prevention of challenge virus transmission from the directly challenged vaccinated ducks to the vaccinated contact animals.
Una vacuna basada en partículas similares a virus proporciona un alto nivel de protección contra el desafío con un virus homólogo de influenza aviar de alta patogenicidad H5N8 en patos mula y Pekin, incluida la prevención de la transmisión. El clado pandémico más reciente de influenza aviar altamente patógena H5, clado 2.3.4.4, se diseminó ampliamente, con la participación de aves silvestres, siendo las aves acuáticas más importantes, portando el virus (incluso asintomáticamente) de Asia a América del Norte, Europa, y África. Las aves acuáticas domésticas en contacto regular con aves silvestres desempeñaron un papel importante en las epizootias H5Nx. Por lo tanto, la protección de las aves acuáticas domésticas contra la infección por influenza aviar H5Nx probablemente cortaría la cadena de transmisión de estos virus y aumentaría en gran medida los esfuerzos para controlar y prevenir brotes de enfermedades en otras aves comerciales y especies animales, así como la infección en humanos. La expectativa de una vacuna de este tipo es no solo brindar protección clínica, sino también controlar la transmisión del virus de desafío de manera eficiente y garantizar que se mantenga la capacidad de diferenciar a los animales vacunados. Se ha desarrollado una vacuna emulsionada en aceite con partículas similares al virus, que contiene el antígeno de hemaglutinina homóloga a las cepas de campo H5N8 europeas actuales, para cumplir con estos requisitos. La vacuna se probó en patos de Pekín y mulas comerciales, vacunándolos una vez, a las tres semanas de edad, o dos veces (al primer día y a las tres semanas de edad). El desafío se realizó a las seis semanas de edad con un aislado de alta patogenicidad H5N8 húngaro (2.3.4.4 Grupo B). La eficacia de la vacunación se evaluó en función de los signos clínicos, la eliminación viral y la transmisión. La vacunación dio como resultado una protección clínica completa y la prevención de la transmisión del virus de desafío de los patos vacunados.
Subject(s)
Ducks , Influenza A Virus, H5N8 Subtype/drug effects , Influenza in Birds/prevention & control , Poultry Diseases/prevention & control , Vaccines, Virus-Like Particle/pharmacology , Viral Vaccines/pharmacology , Animals , Ducks/genetics , Hemagglutinin Glycoproteins, Influenza Virus/administration & dosage , Influenza in Birds/transmission , Poultry Diseases/transmission , Virus Replication/drug effectsABSTRACT
From October 2016 to July 2017, 47 countries have been affected by highly pathogenic avian influenza (HPAI) viruses of the H5N8 clade 2.3.4.4 subtype, including European and African, and it has been the most severe HPAI outbreak ever in Europe. The development of effective influenza vaccines is required to combine preventive and control measures in order to avoid similar avian influenza epidemics taking place. Here we describe a novel prototype recombinant virus-like particle (VLP) vaccine based on a clade 2.3.4.4 H5 HA derived from a French duck HPAI H5N8 isolate of the 2016-2017 epidemics. Prototype vaccines with different antigen content were formulated and the immunogenicity was examined in specific-pathogen-free chickens and in ducks. Serum samples were collected at 3 and 4 weeks postvaccination, and development of the immune response was evaluated by hemagglutination inhibition test and ELISA. The VLP vaccines induced a dose-dependent and high level of antibody response in both chickens and ducks. The results of HPAI H5N8 challenge experiments in ducks are reported separately.
Construcción rápida y pruebas de inmunogenicidad de un nuevo prototipo de vacuna H5 con base en partículas similares a virus contra el clado 2.3.4.4 del virus de la influenza aviar altamente patógeno H5N8. Desde octubre del 2016 hasta julio del 2017, 47 países se han visto afectados por los virus de la influenza aviar altamente patógena del subtipo H5N8 clado 2.3.4.4, incluidos los europeos y africanos y ha sido el brote de influenza aviar de alta patogenicidad más grave en Europa. Se requiere del desarrollo de vacunas efectivas contra la influenza para combinar medidas preventivas y de control para evitar que ocurran epidemias similares de influenza aviar. En este estudio se describe un nuevo prototipo de vacuna recombinante con partículas similares a virus (VLP) basada en una hemaglutinina H5 clado 2.3.4.4 derivada de un aislamiento del virus de influenza aviar de alta patogenicidad H5N8 de patos en Francia presente en las epidemias entre los años 2016 al 2017. Se formularon prototipos de vacunas con diferente contenido de antígeno y se examinó la inmunogenicidad en pollos libres de patógenos específicos y en patos. Las muestras de suero se recolectaron a las tres y cuatro semanas después de la vacunación y el desarrollo de la respuesta inmune se evaluó mediante la prueba de inhibición de la hemaglutinación y ELISA. Las vacunas con partículas similares a virus indujeron un alto nivel de respuesta de anticuerpos dependiente de la dosis tanto en pollos como en patos. Los resultados de los experimentos de desafío con un virus de influenza aviar de alta patogenicidad H5N8 en patos se informan por separado.
Subject(s)
Chickens , Ducks , Influenza A Virus, H5N8 Subtype/drug effects , Influenza in Birds/prevention & control , Poultry Diseases/prevention & control , Vaccines, Virus-Like Particle/pharmacology , Viral Vaccines/pharmacology , Animals , Immunogenicity, Vaccine , Influenza in Birds/transmission , Poultry Diseases/transmission , Specific Pathogen-Free OrganismsABSTRACT
This work aimed to analyze the herd immunity to influenza among a Russian population living in regions with an increased risk of emergence of viruses with pandemic potential, and to isolate and investigate virus strains from severe influenza cases, including fatal cases, during the 2016-2017 epidemic season. In November 2016 - March 2017 highly pathogenic influenza outbreaks were registered in Russia among wild birds and poultry. No cases of human infection were registered. Analysis of 760 sera from people who had contact with infected or perished birds revealed the presence of antibodies to A(H5N1) virus of clade 2.3.2.1c and A(H5N8) virus of clade 2.3.4.4. The 2016-2017 influenza epidemic season in Russia began in weeks 46-47 of 2016 with predominant circulation of influenza A(H3N2) viruses. Strains isolated from severe influenza cases mainly belonged to 3C.2a.2 and 3C.2a.3 genetic groups. Up to the 8th week of 2017 severe influenza cases were often caused by influenza B viruses which belonged to 1A genetic group with antigenic properties similar to B/Brisbane/60/2008. All influenza A and B virus strains isolated in the 2016-2017 epidemic season were sensitive to oseltamivir and zanamivir.
Subject(s)
Antibodies, Viral/blood , Influenza A Virus, H3N2 Subtype/immunology , Influenza A Virus, H5N1 Subtype/immunology , Influenza A Virus, H5N8 Subtype/immunology , Influenza in Birds/epidemiology , Influenza, Human/epidemiology , Poultry Diseases/epidemiology , Animals , Antiviral Agents/therapeutic use , Birds , Epidemics , Humans , Immunity, Herd/immunology , Influenza A Virus, H3N2 Subtype/drug effects , Influenza A Virus, H3N2 Subtype/isolation & purification , Influenza A Virus, H5N1 Subtype/drug effects , Influenza A Virus, H5N1 Subtype/isolation & purification , Influenza A Virus, H5N8 Subtype/drug effects , Influenza A Virus, H5N8 Subtype/isolation & purification , Influenza B virus/drug effects , Influenza B virus/isolation & purification , Influenza, Human/immunology , Influenza, Human/mortality , Influenza, Human/virology , Oseltamivir/therapeutic use , Poultry/virology , Poultry Diseases/virology , Russia/epidemiology , Zanamivir/therapeutic useABSTRACT
Viral neuraminidase inhibitors are widely used as synthetic anti-influenza drugs for the prevention and treatment of influenza. However, drug-resistant influenza A virus variants, including H5N1 highly pathogenic avian influenza viruses (HPAIVs), have been reported. Therefore, the discovery of novel and effective antiviral agents is warranted. We screened the antiviral effects of 11 herbal tea extracts (hibiscus, black tea, tencha, rosehip tea, burdock tea, green tea, jasmine tea, ginger tea, lavender tea, rose tea and oak tea) against the H5N1 HPAIV in vitro. Among the tested extracts, only the hibiscus extract and its fractionated extract (frHibis) highly and rapidly reduced the titers of all H5 HPAIVs and low pathogenic AIVs (LPAIVs) used in the pre-treatment tests of Madin-Darby canine kidney (MDCK) cells that were inoculated with a mixture of the virus and the extract. Immunogold electron microscopy showed that anti-H5 monoclonal antibodies could not bind to the deformed H5 virus particles pretreated with frHibis. In post-treatment tests of MDCK cells cultured in the presence of frHibis after infection with H5N1 HPAIV, the frHibis inhibited viral replication and the expression of viral antigens and genes. Among the plants tested, hibiscus showed the most prominent antiviral effects against both H5 HPAIV and LPAIV.